申请人:Syntex (U.S.A.) Inc.
公开号:US05212195A1
公开(公告)日:1993-05-18
Compound of the Formula (I), (II), or (III): ##STR1## wherein: R.sup.1 is lower alkyl or 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl; R.sup.2 is lower alkyl when R.sup.1 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl; or R.sup.2 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl when R.sup.1 is lower alkyl; R.sup.3 is hydrogen or lower alkyl; X is hydrogen, lower alkyl, halogen, --C(O)CF.sub.3, --CO.sub.2 R.sup.4, or --C(O)NR.sup.5 R.sup.6 ; Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, or --CO.sub.2 R.sup.4 ; Z is hydrogen, lower alkyl, lower alkoxy, or halogen; with the proviso that Y and Z cannot be attached to the nitrogen atom in Formula (II); wherein R.sup.4 is hydrogen or lower alkyl; R.sup.5 is hydrogen or lower alkyl; R.sup.6 is hydrogen or lower alkyl; or R.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a heterocycle; and pharmaceutically acceptable salts thereof, exhibit useful pharmacological properties, and are particularly useful as angiotensin II antagonists.
化合物的结构(I),(II)或(III):##STR1##其中:R.sup.1是较低的烷基或2"-(1H-四唑-5-基)联苯-4'-基甲基;当R.sup.1是2"-(1H-四唑-5-基)联苯-4'-基甲基时,R.sup.2是较低的烷基;或者当R.sup.1是较低的烷基时,R.sup.2是2"-(1H-四唑-5-基)联苯-4'-基甲基;R.sup.3是氢或较低的烷基;X是氢,较低的烷基,卤素,-C(O)CF.sub.3,-CO.sub.2R.sup.4,或-C(O)NR.sup.5R.sup.6;Y是氢,较低的烷基,较低的烷氧基,羟基,卤素,或-CO.sub.2R.sup.4;Z是氢,较低的烷基,较低的烷氧基,或卤素;但Y和Z不能连接到式(II)中的氮原子;其中R.sup.4是氢或较低的烷基;R.sup.5是氢或较低的烷基;R.sup.6是氢或较低的烷基;或R.sup.5和R.sup.6与它们连接的氮一起代表一个杂环;以及其药学上可接受的盐,展示出有用的药理特性,特别适用于作为血管紧张素II拮抗剂。